Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MSCL | Toronto | CAD | Real-time | |
MSCLF | OTC Markets | USD | Delayed | |
MSCL | CBOE Canada | CAD | Real-time |
For the three months ended 31 March 2022, iCo Therapeutics Inc revenues was not reported. Net loss increased from C$862K to C$2.1M. Higher net loss reflects Stock-based compensation (options) increase from C$15K to C$462K (expense), Research and development contracting increase of 67% to C$741K (expense), Management fees increase of 87% to C$411K (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.19 | -2.59 | -11.23 | -1.8 |
Net Income | -2.12 | -2.53 | -11.26 | -1.72 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 10.39 | 12.59 | 14.39 | 0.91 |
Total Liabilities | 1.57 | 2.1 | 2.17 | 2.36 |
Total Equity | 8.83 | 10.48 | 12.22 | -1.45 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -2.09 | -5.03 | -3.77 | -0.79 |
Cash From Investing Activities | -0 | 1.74 | 1.75 | |
Cash From Financing Activities | 0 | 7.45 | 7.58 | 0.43 |
Net Change in Cash | -2.1 | 4.15 | 5.56 | -0.37 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review